Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial

• Published in: The American journal of tropical medicine and hygiene Vol. 66; no. 5; pp. 533 - 541
• Main Authors: Monath, TP, Nichols, R, Archambault, WT, Moore, L, Marchesani, R, Tian, J, Shope, RE, Thomas, N, Schrader, R, Furby, D, Bedford, P
• Format: Journal Article
• Language: English
• Published: Lawrence, KS ASTMH 01.05.2002; Allen Press
• Subjects: Alanine Transaminase - blood; Antibodies, Viral - blood; Arboviroses; Aspartate Aminotransferases - blood; Biological and medical sciences; Double-Blind Method; Human viral diseases; Humans; Infectious diseases; Leukocyte Count; Medical sciences; Platelet Count; Research Design; Sample Size; Tropical medicine; Tropical viral diseases; United Kingdom; Viral diseases; Viral Vaccines - adverse effects; Viral Vaccines - therapeutic use; Yellow fever; Yellow Fever - immunology; Yellow Fever Vaccine - adverse effects; Yellow Fever Vaccine - therapeutic use; Phase III trial; Human; Toxicity; Vaccine; Infection; Prevention; Immunoprophylaxis; Immunogenicity; Viral disease; Arbovirus disease; Clinical trial; Comparative study; Yellow fever

Yellow fever (YF) is a significant health problem in South America and Africa. Travelers to these areas require immunization. The United States, infested with Aedes aegypti mosquitoes, is at risk of introduction of this disease. There is only a single U.S. manufacturer of YF 17D vaccine, and supplie...